GlassScriptPhysician profile
Sarah E Helphinstine
NPI 1396240495
$954.30
in general payments reported to CMS, 2019-2025
21 companies · $82.98 in 2025
The $82.98 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $231 · 2023: $336 · 2024: $191 · 2025: $82.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229.67 | 2023-2025 | |
| Novo Nordisk INC | $103.93 | 2021-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $96.69 | 2021-2023 | Spravato |
| Daiichi Sankyo INC. | $76.57 | 2021-2022 | |
| Amgen INC. | $49.79 | 2023-2025 | Repatha, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $46.82 | 2024-2025 | Fanapt |
| Lilly USA, LLC | $43.05 | 2021-2025 | Mounjaro |
| Axsome Therapeutics, INC. | $37.44 | 2023 | Auvelity, Sunosi |
| Xeris Pharmaceuticals, INC. | $35.60 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $30.73 | 2022-2023 | Seglentis, Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $28.73 | 2022 | |
| Pfizer INC. | $27.85 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.21 | 2021-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $19.27 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.48 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $17.05 | 2025 | Brixadi |
| Mylan Specialty L.P. | $14.81 | 2023 | Yupelri |
| La Jolla Pharmaceutical Company | $14.47 | 2023 | Xerava |
| Merck Sharp & Dohme LLC | $13.42 | 2023 | Vaxelis, Rotateq, Vaxneuvance |
| Organon LLC | $12.59 | 2023 | Nexplanon |
| Corium, LLC | $12.13 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Helphinstine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.